At December’s FDA/CMS Summit in Washington, Health and Human Services Secretary Eric Hargan used Pfizer’s recent price hike of 41 of its products as evidence that higher drug costs are a direct result of the rebate system, a viewpoint touted by the Trump administration in their quest to lower drug prices.
Author: Cathy Kelly
Published: 12 December 2018
Number of pages:2
How do we fix high list prices? The Trump administration remains convinced that the answer lies in pointing the finger at the rebating system, and instituting changes to it. When Pfizer recently announced an increase in list prices for 10% of their drugs (41 in all), Health and Human Services Secretary Eric Hargan used it as evidence that changing the rebate system is the pathway to lowering drug costs overall. Read more about Hargan’s comments on the matter, made during December’s FDA/CMS Summit in Washington, in this essential Pink Sheet article.
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.